Recently, we found nonsense and missense mutations of the PPP1R3 (protein phosphatase 1, regulatory subunit 3) gene in diverse human cancer cell lines and primary lung carcinomas, indicating that PPP1R3 functions as a tumor suppressor in human carcinogenesis. In this study, to assess the prevalence of PPP1R3 mutations in human primary cancers and the genetic diversity of the PPP1R3 gene in the human population, somatic mutations and genetic polymorphisms in the PPP1R3 gene were examined in 137 pairs of cancerous and non-cancerous tissues of patients with cancers of colon, ovary, and liver. Five somatic mutations including two missense mutations were detected in three cancerous tissues consisting of two colorectal carcinomas and one ovarian carcinoma. Five novel single nucleotide polymorphisms (SNPs) associated with the substitution of amino acids were also identi®ed in cancer patients, in addition to ®ve known nonsynonymous SNPs, including three previously reported ones as having an impact on the susceptibility to insulin resistant disorders. Dierences in the activities and properties of multiple PPP1R3 proteins, which are produced in human cells due to variable somatic mutations and genetic polymorphisms in the PPP1R3 gene, can be involved in human carcinogenesis and susceptibility to diseases. Oncogene (2000) 19, 836 ± 840.
Keywords: protein phosphatase 1; PPP1R3; mutation; single nucleotide polymorphism; tumor suppressor gene Protein phosphatases (PPs) have important roles in regulating a variety of cellular processes, including metabolism, cell cycle, and intracellular signaling (Parsons, 1998) . It has been speculated that PPs function as tumor suppressors by antagonizing protein kinases, many of which act as oncoproteins Parsons, 1998) . In fact, recent studies have indicated that two PP genes are inactivated by somatic genetic alterations in human cancers. One is the PTEN/ MMAC1 gene encoding a dual-speci®city PP, which was inactivated in a variety of human cancers, including glioma, prostate carcinoma, melanoma, endometrial carcinoma, and lung carcinoma Steck et al., 1997; Kohno et al., 1998a) . The other is the PPP2R1B gene encoding a regulatory subunit of PP2A, which was mutated in lung and colorectal carcinomas (Wang et al., 1998) . Recent results also indicate that genetic variations of these two PP genes are involved in the susceptibility to tumor development. Germline PTEN mutations have been reported to be responsible for several autosomal dominant cancer preposition syndromes including Cowden Disease Nelen et al., 1997; Eng, 1998; Kohno et al., 1998b) . In addition, a nucleotide substitution of the PPP2R1B gene, which was detected as somatic mutation in two lung carcinomas, was also detected in the germline of a lung cancer patient (Wang et al., 1998) . Therefore, it is possible that some genetic variations of the PPP2R1B gene have a causative signi®cance on the enhanced susceptibility to cancer.
PP1 plays an important role in cell cycle regulation, RNA splicing and glycogen metabolism, and is a target for chemical tumor promoters (Fujiki and Suganuma, 1993; Mermoud et al., 1994; Faux et al., 1996; Kawabe et al., 1997; Rubin et al., 1998) . The PP1A holoenzyme exists as a dimer consisting of a catalytic subunit and a regulatory subunit, which modulates physiological functions of PP1 by regulating enzymatic activity and speci®city. PPP1R3 protein, a polypeptide of 1122 amino acids corresponding to the regulatory subunit 3 of PP1, is reported as being involved in directing the PP1 catalytic subunit(s) to glycogen particles or to the membranes of sarcoplasmic reticulum (Faux et al., 1996) . The PPP1R3 gene is located at chromosome band 7q31, where chromosome deletions occur in various types of human cancers, including carcinomas of lung, breast, stomach, colon, kidney, and ovary and hematological malignancies (Zenklusen et al., 1995 (Zenklusen et al., , 1999 Shiseki et al., 1996; Koike et al., 1997; Liang et al., 1998) . Recently, we found nonsense and missense mutations of the PPP1R3 gene in primary non-small cell lung carcinomas (NSCLCs) and the cell lines derived from lung carcinoma, ovarian carcinoma, colorectal carcinoma, and gastric carcinoma (Kohno et al., 1999) . The result suggests that PPP1R3 acts as a tumor suppressor in human carcinogenesis.
In the course of our mutational study, two single nucleotide polymorphisms (SNPs) in the coding region of the PPP1R3 gene were identi®ed (Kohno et al., 1999) , and they were associated with changes of evolutionally conserved amino acids (Chen et al., 1994) . Three other SNPs associated with amino acid changes and a variation in the 3'-untranslated region have already been identi®ed in the PPP1R3 gene (Chen et al., 1994; Hansen et al., 1995; Xia et al., 1998) . Since carriers of minor alleles for these four polymorphisms showed reduced activity of insulin-stimulated glycogen metabolism in vivo, genetic variations of PPP1R3 have an impact on the susceptibility to insulin resistant disorders. Therefore, it was speculated that the PPP1R3 gene has high genetic variations associated with the dierence in the enzyme activity in the human population.
In this study, to assess the prevalence of PPP1R3 mutations in human cancer and the genetic diversity of the PPP1R3 gene in the human population, somatic mutations and genetic polymorphisms of the PPP1R3 gene were examined by PCR ± SSCP analysis and direct sequencing in 137 pairs of cancerous and noncancerous tissue samples, which were obtained from 55 patients with colorectal carcinomas, 46 patients with ovarian carcinomas and 36 patients with hepatocellular carcinomas.
Two (4%) of the 55 colorectal carcinomas and one (2%) of the 46 ovarian carcinomas showed somatic mutations (Table 1, Figure 1 ), that is, mobility shifts were detected only in cancerous tissues and not in the corresponding non-cancerous tissues. A colorectal carcinoma, 2007T, had triple mutations consisting of two missense mutations and a silent mutation. A missense mutation at codon 1086 caused substitution of a hydrophobic amino acid, leucine, in the potential transmembrane region to a hydrophilic amino acid, arginine, and the remaining one at codon 934 caused substitution of an evolutionary conserved amino acid, valine to alanine. A silent mutation at codon 213 in exon 1 was also detected in this case. The results of PCR ± SSCP and sequence analyses are shown in Figure 1b ,c. A point mutation of A to T at +66 nucleotides from exon 1 was found in a colorectal carcinoma 2092T. In a primary ovarian carcinoma OV5T, a silent mutation was detected at codon 85 in exon 1. No somatic mutations of the PPP1R3 gene were detected in hepatocellular carcinomas. It appeared that wild-type alleles were retained in all the tumors with PPP1R3 mutations. However, the tumor materials were macroscopically dissected in this study, therefore, it was unclear whether or not these PPP1R3 mutations were really heterozygous due to contamination of non-cancerous cells in the materials.
Seven coding region SNPs were detected in 137 DNA samples obtained from non-cancerous tissues of the patients (Figure 1a ). All of them were associated with amino acid changes. Two of them were previously reported and were common SNPs of allele frequencies of more than 1% at codons 883 and 905 of the PPP1R3 gene (Hansen et al., 1995; Xia et al., 1998) . The remaining ®ve were novel and resulted in amino acid substitutions at codons 625, 629, 767, 852 and 1096 (Table 2) . Each novel SNP was detected as a heterozygote in one of 137 individuals. Therefore, they are rare SNPs whose allele frequencies are less than 1% in the Japanese population. The results of PCR ± SSCP and sequence analyses for D629V and E767K polymorphisms in cases OV7 and 2042, respectively, are shown in Figure 1b ,c. None of the ®ve novel SNPs were observed in 104 cell lines and 50 normal lung tissue samples obtained from lung cancer patients (Kohno et al., 1999) . In our previous study, two other SNPs at codons 600 and 494 were detected in one and two individuals respectively (Table 2 ). In addition, a SNP at codon 931 had previously been detected in a non-insulin-dependent diabetes mellitus (NIDDM) patient (Chen et al., 1994) . However, these three polymorphisms were not observed in this study.
We next examined PPP1R3 expression in four colorectal and four ovarian cancer cell lines by RT ± PCR analysis using a set of primers which amplify a 153 nt cDNA fragment encompassing exons 3 and 4 of the PPP1R3 gene. We also examined PPP1R3 expression in nine pairs of primary colorectal carcinomas and adjacent non-cancerous colorectal tissues and seven pairs of primary ovarian carcinomas and adjacent non-cancerous ovarian tissues. Transcripts of the PPP1R3 gene were detected in all cancer cell lines examined, including an ovarian cancer cell line, SKOV3, in which mutation of the PPP1R3 gene was detected (Kohno et al., 1999) (Figure 2 ). PPP1R3 transcripts were also detected in all primary tumors and adjacent non-cancerous tissues of colon and ovary (Figure 2) .
In this study, somatic PPP1R3 mutations were examined in 137 cancerous tissues. Five mutations were found in primary colorectal and ovarian carcinomas, while mutations were not detected in hepatocellular carcinomas. The mutations consisted of two missense mutations, two silent mutations, and a mutation in the intron sequence. Three of the ®ve mutations were identi®ed in a case of colorectal carcinoma. RT ± PCR analysis in this study showed that the PPP1R3 gene is expressed in cancer cells as well as normal tissues of colon and ovary. Therefore, PPP1R3 alterations may cause a disturbance of the physiological function of PP1. The two missense mutations caused amino acid substitutions which are predicted as having eects on the activity of the PPP1R3 protein. A point mutation in intron 1 and two silent mutations were also observed. Intronic mutations as well as silent mutations have been often observed in several tumor suppressor genes in human cancers (Cho et al., 1994; Strauss, 1998; Takenoshita et al., 1998) . It has been shown that several nucleotide substitutions, which are not associated with amino acid change, have eects on mRNA stability, eciency in transcription and translation (Isacchi et al., 1989; Milland et al., 1996; Xia et al., 1998) . Therefore, these three PPP1R3 mutations might have the functions of giving an advantage to the growth of tumor cells by changing the intracellular PPP1R3 activity. The results to date indicate that the PPP1R3 gene is mutated in a small fraction of diverse cancers, including primary tumors. However, it is possible that the PPP1R3 gene is frequently mutated in a speci®c type of cancer. Therefore, further mutation analyses will be necessary (Chen et al., 1994; Eglo et al., 1997) . Filled, gray, and open arrowheads indicate the positions of nonsense, missense, and silent mutations detected in cancer cells, respectively. Arrows indicate the positions of genetic polymorphisms. Nucleotide substitutions detected in this study are underlined. (b) PCR ± SSCP analysis. Representative results of PCR ± SSCP analysis using primer pairs of 1aF and 1aR, 1bF and 1bR, 4dF and 4dR, and 4eF and 4eR are shown. Tissue samples were obtained from 55 patients with colorectal carcinomas who were treated at the National Cancer Center Hospital, Tokyo, 46 patients with ovarian carcinomas who were treated at the Jikei University Hosptial, Tokyo, and 36 patients with hepatocellular carcinomas who were treated at the Gunma University Hospital, Maebashi. The materials that were macroscopically entirely tumorous were dissected and stored at 7708C until DNA extraction. High-molecular-weight DNA was prepared from tumors and adjacent non-cancerous tissues by proteinase K digestion and phenol extraction (Sakamoto et al., 1986) . Nucleotide substitutions in exons 1 to 4 covering the entire coding region of the PPP1R3 gene were examined by the PCR ± SSCP method with eight sets of PCR primers: 1aF and 1aR, and 1bF and 1bR for exon 1, 2/3F and 2/3R for exons 2 and 3, 4aF and 4aR, 4bF and 4bR, 4cF and 4cR, 4dF and 4dR, and 4eF and 4eR for exon 4 as described previously (Kohno et al., 1999) . Fifty ng of genomic DNA were subjected to PCR in a total volume of 20-ml PCR buer containing 1.5 mCi of [a-32 P]dCTP (Amersham Pharmacia Biotech) under the following conditions; 60 s at 958C, 60 s at 558C, and 90 s at 728C for 35 cycles, followed by 10 min at 728C and subjected for SSCP analysis after digestion with appropriate restriction enzymes as described previously (Kohno et al., 1999) . SSCP analysis was performed in a low pH buer system that showed improved separation of long mutant fragments of up to 800 base pairs (Kukita et al., 1997) . Gels were dried and exposed to Kodak XAR ®lms for 24 to 48 h at 7808C. Shifted bands are indicated by arrows. T: cancerous tissue, N: noncancerous tissue. (c) Sequence analysis. PCR products showing dierent mobilities were puri®ed by using a QIA quick-spin PCR puri®cation kit (QIAGEN), and directly sequenced in both directions with Thermo-Sequence dye terminator cycle sequencing premix kits (Amersham Pharmacia Biotech) and the ABI 373S DNA Sequence System (PERKIN-ELMER). In 2007 (1bR) and 2007 (4eR), histograms for the sequencing in reverse direction are shown. The substituted nucleotides are underlined. Primers used for the sequencing are described on the left were detected in the coding region of the PPP1R3 gene, and were associated with changes of amino acids. In the minor alleles for the nine of the SNPs excluding the one at codon 883, amino acids which have been evolutionally conserved were substituted to others (Chen et al., 1994) . Therefore, it is possible that these genetic polymorphisms cause interindividual dierences in the activity of the PPP1R3 protein. Interestingly, it was reported that several SNPs have biological signi®cance on glycogen metabolism. The S883 and Y905 alleles were associated with decreased insulin stimulated glycogen synthesis when compared with the R883 and D905 alleles, respectively (Hansen et al., 1995; Xia et al., 1998 ). An NIDDM patient de®ned as an E931 carrier also showed a poor responsiveness to insulin (Chen et al., 1994) . We do not have information on the insulin resistance of the cancer patients who were de®ned as carriers of minor alleles for the novel SNPs in this study. All of the seven SNPs we identi®ed in cancer patients were not detected in previous analyses of 141 individuals consisting of NIDDM patients and healthy controls (Chen et al., 1994; Hansen et al., 1995; Xia et al., 1998) . Therefore, it is possible that minor alleles for these SNPs are observed preferentially in cancer patients, and some alleles are associated with the enhanced susceptibility to cancer. The low allele frequency of the minor alleles for these SNPs might re¯ect selection acting against deleterious alleles during evolution. It would be interesting to examine whether novel genetic variants of PPP1R3 have an impact on the susceptibility to cancer. For this reason, a case control study of SNPs in the PPP1R3 gene between cancer patients and healthy individuals is now in progress in our laboratory.
Somatic mutations and genetic polymorphisms of the PPP1R3 gene lead to the production of multiple PPP1R3 proteins in human cells, which are supposed to have dierent enzyme activities. The PPP1R3 protein plays a critical role in the regulation of PP1 activity, which is involved in cell cycle regulation, mRNA splicing and glycogen metabolism (Faux et al., 1996; Rubin et al., 1998) . Therefore, mutant PPP1R3 protein in human cancer cells might have a role in the clonal expansion of cancer cells by disturbing the intra cellular signaling pathway via PP1. Interindividual variations in PPP1R3 activity due to a combination of PPP1R3 polymorphisms could be a genetic factor for susceptibility to diseases. Functional and epidemiological analyses of the PPP1R3 variants detected in cancerous and non-cancerous cells should be performed to elucidate the implication of PPP1R3 diversity in human disease. Two rare polymorphisms detected previously (Kohno et al., 1999) Figure 2 PPP1R3 expression in colorectal and ovarian cancer cells detected by RT ± PCR analysis. Poly(A) + mRNA was prepared from four colorectal cancer cell lines (DLD-1, LoVo, HCT116, HCT15), four ovarian cancer cell lines (A2780, SKOV3, SW626, OV1063), nine pairs of primary colorectal carcinomas and adjacent non-cancerous colorectal tissues, and seven pairs of primary ovarian carcinomas and adjacent non-cancerous ovarian tissues by the Fast Track mRNA isolation kit (Invitrogen). Poly(A) + mRNA from human normal lung and intestinal tissue was purchased from Clontech. Randomly primed cDNAs were reverse-transcribed from 0.5 mg mRNAs by using SuperScriptII Reverse Transcriptase (Gibco BRL) according to supplier's protocol. One microliter of the cDNA conversion mixture was ampli®ed by PCR under the following conditions; 60 s at 958C, 60 s at 608C, and 60 s at 728C for 40 cycles (for PPP1R3) or 30 cycles (for GAPDH), followed by 10 min at 728C. A set of primers, 5'-TTGTTCTCATGAGGACAAGGA-3' and 5'-TTCATCTCTGGAAGCAGTACT-3', was used for the PPP1R3 gene, and a set of primers, 5'-CCAAGGTCATCCATGACAAC-3' and 5'-CACCCTGTTGCTGTAGCCA-3', was used for the GAPDH gene. PCR products were electrophoresed on 3.0% agarose gel and stained with ethidium-bromide. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was analysed to standardize the amount of RNA in each sample. T: cancerous tissue, N: non-cancerous tissue. 1 ± 3: primary colorectal carcinomas and adjacent non-cancerous colorectal tissues, 4 ± 6: primary ovarian carcinomas and adjacent non-cancerous ovarian tissues
